83 related articles for article (PubMed ID: 6064867)
1. Report of the Subcommittee on Human Factor 8 (AHF) Preparations.
Wagner RH
Thromb Diath Haemorrh Suppl; 1967; 26():371-5. PubMed ID: 6064867
[No Abstract] [Full Text] [Related]
2. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia.
Lange D; Lazerson J
Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446
[No Abstract] [Full Text] [Related]
3. Psychosocial issues surrounding the general or restricted use of recombinant factor VIII: hemophilia clinic perspective.
McDonald JR
Transfus Med Rev; 1992 Oct; 6(4):277-9. PubMed ID: 1421829
[No Abstract] [Full Text] [Related]
4. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
Yee TT; Lee CA
Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
[No Abstract] [Full Text] [Related]
5. Obtention production and use of factor VIII in Costa Rica.
Cordero R; Montero C
Scand J Haematol Suppl; 1984; 40():509-11. PubMed ID: 6433473
[No Abstract] [Full Text] [Related]
6. Recommendations of the subcommittee on human factor VIII (AHF) and factor IX (PTC) preparations.
Wagner RH
Thromb Diath Haemorrh Suppl; 1968; 35():235-7. PubMed ID: 5761065
[No Abstract] [Full Text] [Related]
7. In vivo characteristics of thaw siphon cryoprecipitate compared to other factor VIII preparations.
Toolis F; McKay G; Prowse CV
Thromb Haemost; 1980 Feb; 43(1):25-7. PubMed ID: 6773169
[TBL] [Abstract][Full Text] [Related]
8. To what extent can plasma supply for factor VIII production, be obtained within the frame of a blood component program?
Högman CF
Scand J Haematol Suppl; 1984; 40():485-90. PubMed ID: 6433469
[No Abstract] [Full Text] [Related]
9. Proceedings: Factor VIII replacement in the treatment of haemophilia A--a simple illustration of a need-supply-demand spiral.
Spencely M; Cash JD
Br J Prev Soc Med; 1974 Feb; 28(1):71. PubMed ID: 4816606
[No Abstract] [Full Text] [Related]
10. Factor VIII supply and demand.
Aronstam A
Br Med J; 1980 Jun; 280(6230):1532-3. PubMed ID: 6770955
[No Abstract] [Full Text] [Related]
11. [The value of AHF-prophylaxis].
Olin P
Lakartidningen; 1968 Mar; 65(10):1031-2 passim. PubMed ID: 5720700
[No Abstract] [Full Text] [Related]
12. Factor VIII international units and reference materials.
Bangham DR; Brozović M
Thromb Diath Haemorrh; 1974 Mar; 31(1):3-11. PubMed ID: 4836134
[No Abstract] [Full Text] [Related]
13. Plasma resource planning in Canada.
Grove G; Strawczynski H; Derrick JB
Scand J Haematol Suppl; 1984; 40():505-7. PubMed ID: 6433472
[No Abstract] [Full Text] [Related]
14. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
Gaerisch F; Stein P
Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530
[TBL] [Abstract][Full Text] [Related]
15. Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques.
Bennett B; Ratnoff OD
J Clin Invest; 1972 Oct; 51(10):2593-6. PubMed ID: 4626847
[TBL] [Abstract][Full Text] [Related]
16. Fifteen years of population based experience in Finland with a plasma-derived monoclonal purified factor VIII concentrate.
Mäkipernaa A; von Bonsdorff L
Haemophilia; 2008 May; 14(3):612-4. PubMed ID: 18312362
[No Abstract] [Full Text] [Related]
17. Can hemophilic patients be adequately maintained with cryoprecipitates? Or is it desirable or even necessary to manufacture and administer highly concentrated AHF products?
Vox Sang; 1972; 22(6):554-65. PubMed ID: 5050492
[No Abstract] [Full Text] [Related]
18. Very-high-purity versus intermediate-purity factor VIII in human immunodeficiency virus-positive hemophiliacs: conclusions of a prospective 3-year study. Monoclate Study Group.
Seremetis SV
Semin Hematol; 1993 Oct; 30(4 Suppl 5):10-3. PubMed ID: 7903480
[No Abstract] [Full Text] [Related]
19. Choice of replacement therapy for hemophilia-cryoprecipitate issues: a rebuttal.
Farrugia A; Giangrande P
J Thromb Haemost; 2004 Jun; 2(6):1022-3. PubMed ID: 15140151
[No Abstract] [Full Text] [Related]
20. [The treatment of hemophilia A with a new antihemophilic fraction "AHF SRK (human)". Comparison with the antihemophilic globulin AHG SRK].
Duckert F; Müller G; Meili EO
Schweiz Med Wochenschr; 1971 Dec; 101(50):1831-8. PubMed ID: 5173501
[No Abstract] [Full Text] [Related]
[Next] [New Search]
